{"id":"W4399519785","doi":"10.1200/jco.2024.42.16_suppl.6516","title":"Safety outcomes in patients with acute myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to allogeneic hematopoietic stem cell transplantation.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Gemtuzumab ozogamicin; Medicine; Myeloid leukemia; Stem cell; Hematopoietic stem cell transplantation; Transplantation; Hematopoietic cell; Haematopoiesis; Leukemia; Oncology; Internal medicine; CD34; CD33","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154768,0.0001877609,0.0004399862,0.0004267486,0.0003204326,0.0006292996,0.0001939398,0.0002928871,0.001024254],"category_scores_gemma":[0.002331546,0.0001337557,0.0006094516,0.0006478304,0.0001981713,0.0003697875,0.000347463,0.000470856,0.0001841728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006813338,"about_ca_system_score_gemma":0.0006145806,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007580717,"about_ca_topic_score_gemma":0.001178176,"domain_scores_codex":[0.9992918,0.000164468,0.0001363189,0.0001317518,0.000169359,0.0001062523],"domain_scores_gemma":[0.9971231,0.0003416884,0.002013211,0.00009122615,0.0001687623,0.0002619978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00309222,0.0002196432,0.9847817,0.00006610539,0.0001916285,0.0001980802,0.00007499285,0.0002477843,0.0005870261,0.00004042036,0.0003830306,0.01011731],"study_design_scores_gemma":[0.0003592603,0.003681224,0.9915972,0.00003518822,0.0002195293,0.001125681,0.0001141191,0.0005918849,0.0006861986,0.00008187775,0.001498177,0.000009783632],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974753,0.0007631762,0.000105599,0.00007441114,0.000007782874,0.00004008866,0.0009052877,0.000005299604,0.0006231301],"genre_scores_gemma":[0.9973489,0.0002016011,0.0001076192,0.0001052468,0.00002388301,0.00003721013,0.002014663,0.000001725876,0.0001592291],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001154768,"threshold_uncertainty_score":0.006107032,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04017881417414301,"score_gpt":0.3864102243190257,"score_spread":0.3462314101448827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}